Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Intangibles (2016 - 2025)

Ironwood Pharmaceuticals' Intangibles history spans 5 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Intangibles fell 28.67% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 28.67%, while the annual FY2025 figure was $2.0 million, 28.67% down from the prior year.
  • Intangibles for Q4 2025 was $2.0 million at Ironwood Pharmaceuticals, down from $2.2 million in the prior quarter.
  • Across five years, Intangibles topped out at $4.1 million in Q2 2023 and bottomed at $2.0 million in Q4 2025.
  • The 3-year median for Intangibles is $3.1 million (2024), against an average of $3.1 million.
  • The largest annual shift saw Intangibles decreased 20.09% in 2024 before it dropped 28.67% in 2025.
  • A 3-year view of Intangibles shows it stood at $3.7 million in 2023, then dropped by 22.32% to $2.9 million in 2024, then fell by 28.67% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Intangibles are $2.0 million (Q4 2025), $2.2 million (Q3 2025), and $2.5 million (Q2 2025).